BioCryst Pharmaceuticals Says Data From Open-label Extension Of APEX-2 Trial Of Orladeyo For Prophylactic Treatment Of Hereditary Angioedema In Patients 12 Years And Older Have Been Published Online By Journal Of Allergy & Clinical Immunology: In Practice
BioCryst Pharmaceuticals Says Data From Open-label Extension Of APEX-2 Trial Of Orladeyo For Prophylactic Treatment Of Hereditary Angioedema In Patients 12 Years And Older Have Been Published Online By Journal Of Allergy & Clinical Immunology: In Practice
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.